ClinicalTrials.Veeva

Menu

Phase Analysis and Obstructive CAD on Rubidium PET

Emory University logo

Emory University

Status and phase

Withdrawn
Phase 2

Conditions

Coronary Artery Disease

Treatments

Drug: Regadenoson

Study type

Interventional

Funder types

Other

Identifiers

NCT01840696
REGA12I11 (Other Identifier)
IRB00062632

Details and patient eligibility

About

Rubidium myocardial perfusion PET is an imaging test used to diagnose patients with abnormal blood flow to the heart secondary to narrowing of the heart vessels.

Phase analysis is a computer method that is applied after the PET test is done. It is used to determine when a region of the heart contracts relative to other heart regions in the heart beating cycle. Initial data suggest that regions of the heart with abnormal blood flow change the pattern of contraction from rest to stress conditions. That is, regions of the heart with abnormal blood supply become dyssynchronous when compared to the normal regions of the heart.

This study will investigate whether phase analysis may aid the visual interpretation of rubidium myocardial perfusion PET studies by determining the areas of the heart that are not beating in synchrony with the normal heart regions. This information will be used as a proxy for poor blood supply. The gold standard will be coronary angiography by which the percent narrowing of the heart vessels is assessed.

Sex

All

Ages

18 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female patients
  • referred for myocardial perfusion imaging for suspected obstructive CAD
  • 18 years of age or older.

Exclusion criteria

  • Contraindications to regadenoson radionuclide imaging including severe reactive airway disease, unstable crescendo angina, high grade AV block, caffeine within 24 hours
  • Documented prior myocardial infarction
  • Severe claustrophobia
  • Patients who may be pregnant.

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

0 participants in 1 patient group

Regadenoson
Experimental group
Treatment:
Drug: Regadenoson

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems